Title |
MicroRNA-155—at the Critical Interface of Innate and Adaptive Immunity in Arthritis
|
---|---|
Published in |
Frontiers in immunology, January 2018
|
DOI | 10.3389/fimmu.2017.01932 |
Pubmed ID | |
Authors |
Stefano Alivernini, Elisa Gremese, Charles McSharry, Barbara Tolusso, Gianfranco Ferraccioli, Iain B. McInnes, Mariola Kurowska-Stolarska |
Abstract |
MicroRNAs (miRNAs) are small non-coding RNAs that fine-tune the cell response to a changing environment by modulating the cell transcriptome. miR-155 is a multifunctional miRNA enriched in cells of the immune system and is indispensable for the immune response. However, when deregulated, miR-155 contributes to the development of chronic inflammation, autoimmunity, cancer, and fibrosis. Herein, we review the evidence for the pathogenic role of miR-155 in driving aberrant activation of the immune system in rheumatoid arthritis, and its potential as a disease biomarker and therapeutic target. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 14% |
Venezuela, Bolivarian Republic of | 1 | 7% |
Canada | 1 | 7% |
Benin | 1 | 7% |
Switzerland | 1 | 7% |
Unknown | 8 | 57% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 10 | 71% |
Scientists | 3 | 21% |
Science communicators (journalists, bloggers, editors) | 1 | 7% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 189 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 35 | 19% |
Student > Bachelor | 23 | 12% |
Researcher | 20 | 11% |
Student > Master | 15 | 8% |
Student > Doctoral Student | 10 | 5% |
Other | 31 | 16% |
Unknown | 55 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 40 | 21% |
Immunology and Microbiology | 23 | 12% |
Medicine and Dentistry | 22 | 12% |
Agricultural and Biological Sciences | 16 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 3% |
Other | 23 | 12% |
Unknown | 60 | 32% |